64 hispeed spiral scanner

Patient selection and treatment are presented in Table 1. In a singlecenter study, 16 adult HL patients treated with anti-PD1 were retrospectively selected, 15 treated by pembrolizumab intravenously in clinical trials (NCT01953692, NCT02453594) and 1 treated by nivolumab intravenously in a compassionate program. Patients were treated for HL relapsing or refractory to salvage chemotherapy including brentuximab vedotin and autologous stem cell transplantation at Gustave Roussy, from December 2013 to December 2015. All patients underwent 18 F-FDG PET and contrast-enhanced CT evaluations at baseline and every 3 mo until progression or cessation of treatment for up to 2 y. The protocols (NCT01953692 and NCT02453594) were approved by ethics committee, and all subjects signed a written informed consent form. 18 F-FDG PET and CT Scan Acquisitions 18 F-FDG PET/CT images were acquired and reconstructed according to guidelines (25) using a Discovery 690 (GE Healthcare) with an activity of 3-4 MBq/kg of 18 F-FDG, a 2-min-per-bed acquisition time, and a 90-min delay after 18 F-FDG injection. Whole-body CT scans were acquired using a 64 HiSpeed spiral scanner (GE Healthcare) after administration of intravenous contrast agent.